| Literature DB >> 31066025 |
Francesco Nicita1, Marta Nardella1, Emanuele Bellacchio2, Paolo Alfieri3, Gaetano Terrone4, Giorgia Piccini3, Federica Graziola5, Claudio Pignata4, Alessandro Capuano5, Enrico Bertini1, Ginevra Zanni1.
Abstract
Heterozygous missense variants in the SPTBN2 gene, encoding the non-erythrocytic beta spectrin 2 subunit (beta-III spectrin), have been identified in autosomal dominant spinocerebellar ataxia type 5 (SCA5), a rare adult-onset neurodegenerative disorder characterized by progressive cerebellar ataxia, whereas homozygous loss of function variants in SPTBN2 have been associated with early onset cerebellar ataxia and global developmental delay (SCAR14). Recently, heterozygous SPTBN2 missense variants have been identified in a few patients with an early-onset ataxic phenotype. We report five patients with non-progressive congenital ataxia and psychomotor delay, 4/5 harboring novel heterozygous missense variants in SPTBN2 and one patient with compound heterozygous SPTBN2 variants. With an overall prevalence of 5% in our cohort of unrelated patients screened by targeted next-generation sequencing (NGS) for congenital or early-onset cerebellar ataxia, this study indicates that both dominant and recessive mutations of SPTBN2 together with CACNA1A and ITPR1, are a frequent cause of early-onset/congenital non-progressive ataxia and that their screening should be implemented in this subgroup of disorders.Entities:
Keywords: SCA5; SCAR14; SPTBN2; beta-III spectrin; congenital ataxia; spinocerebellar ataxia
Mesh:
Substances:
Year: 2019 PMID: 31066025 DOI: 10.1111/cge.13562
Source DB: PubMed Journal: Clin Genet ISSN: 0009-9163 Impact factor: 4.438